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Urinary peptide panel for 
prognostic assessment of bladder 
cancer relapse
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Martin pejchinovski1, Antonia Vlahou4, Harald Mischak1 & Maria Frantzi1
Non-invasive tools stratifying bladder cancer (BC) patients according to the risk of relapse are urgently 
needed to guide clinical intervention. As a follow-up to the previously published study on Ce-Ms-
based urinary biomarkers for BC detection and recurrence monitoring, we expanded the investigation 
towards BC patients with longitudinal data. Profiling datasets of BC patients with follow-up information 
regarding the relapse status were investigated. the peptidomics dataset (n = 98) was split into training 
and test set. Cox regression was utilized for feature selection in the training set. Investigation of the 
entire training set at the single peptide level revealed 36 peptides being strong independent prognostic 
markers of disease relapse. those features were further integrated into a Random Forest-based model 
evaluating the risk of relapse for BC patients. performance of the model was assessed in the test cohort, 
showing high significance in BC relapse prognosis [HR = 5.76, p-value = 0.0001, c-index = 0.64]. Urinary 
peptide profiles integrated into a prognostic model allow for quantitative risk assessment of BC relapse 
highlighting the need for its incorporation in prospective studies to establish its value in the clinical 
management of BC.
Bladder cancer (BC) is among the most common and costliest malignancies worldwide1. Although the majority 
of BC cases are non-muscle invasive (NMIBC), BC is characterized by high recurrence (~70%) and progression 
rates (10–20%) to muscle-invasive disease (MIBC)2–4. As such, NMIBC patients undergo life-long surveillance 
through invasive cystoscopy. Based on the guidelines, different treatment schemes are recommended for NMIBC5 
and MIBC6. High-grade NMIBC patients are treated with Bacillus Calmette-Guérin (BCG) immunotherapy or 
intravesical instillation of mitomycin-C/epirubicin (chemotherapy)5, while MIBC patients undergo radical cys-
tectomy6. Extensive genomic characterization of BC revealed high tumor heterogeneity indicating the existence 
of distinct disease molecular subtypes7,8. In fact, growing evidence suggests that BC represents a group of hetero-
geneous diseases, both molecularly and clinicopathologically9,10.
As novel therapeutic interventions for BC are on the rise, including immune checkpoint inhibitors targeting 
Programmed cell Death (PD)-1 receptor and its ligand PD-L1, as well as cytotoxic T-lymphocyte-associated 
Protein 4 (CTLA4), guiding intervention through the stratification of BC patients according to the risk for 
relapse and/or to the predicted drug response becomes even more critical in the selection of optimal treatment 
approach. Therefore, complementary biomarkers are still needed to improve prognostic certainty and guide clin-
ical intervention.
So far, a risk assessment approach is applied for identifying probabilities of recurrence and progression. 
Currently used risk calculators are based on clinical and pathological characteristics. Major predictive models 
that are used in clinical practice include11: (1) the European Organization for Research and Treatment of Cancer 
(EORTC) risk tables for the probabilities of recurrence and progression after TURBT12; (2) the Spanish Urological 
Club for Oncological Treatment scoring model (CUETO) for the risk of recurrence and progression after BCG 
therapy13; and (3) the updated EORTC risk groups for recurrence, progression, and disease-specific and overall 
survival for high-risk NMIBC patients receiving the BCG maintenance therapy14. The initial EORTC risk tables 
were constructed based on the six most relevant predictors of outcomes i.e. tumor stage and grade, number 
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and size of tumors, carcinoma in situ (CIS), and prior recurrence rate. To account for the patients treated with 
BCG (low in number during EORTC risk tables’ development), an optimized scoring model was developed by 
CUETO introducing 1062 BCG-treated patients and including age and gender in the risk assessment equation. 
Updated EORTC risk tables for early recurrence include: prior recurrence rate, number of tumors and grade as 
main parameters, while variables in the late recurrence model consist of prior recurrence rate and number of 
tumors. Despite their potential in clinical practice, there are several limitations of these models, mainly involving 
the high complexity of the first two and over-simplicity of the latter, not being able to embrace BC heterogeneity 
at the molecular level. Moreover, as EORTC risk tables tend to overestimate15, while CUETO scoring model can 
underestimate the risk of disease recurrence/progression16, more precise prognostic models are much needed.
Urine has been already recognized as an exceptional source of biomarkers, due to the high stability of the 
proteome and non-invasive means of collection17. Moreover, urinary peptides carry substantial information not 
only for on-site but also for systemic events that are related to BC and depict molecular changes linked to disease 
pathophysiology e.g. tumor invasion and inflammation.
Mass spectrometry-derived (CE-MS) urinary profiling data have been previously explored for detection of 
BC18, as well as discrimination of non- from muscle-invasive form of BC19. More recently, two diagnostic panels, 
based on the same technology, were published for BC detection (BC-116) and monitoring of recurrence (BC-
106)20. In the latter, the urinary profiles were also indicative of disease molecular changes during BC progression.
In this proof-of-principle study, the previously published peptidomics datasets based on the CE-MS analysis 
of urine from BC patients, have been evaluated in a prognostic setting for patients with available follow-up data. 
The aim of this investigation was dual: a) to evaluate the prognostic value of the previously published diagnostic 
panel (BC-106) in the form of support vector machine classifier (SVM) with regards to BC relapse and b) to inves-
tigate the prognostic value of individual peptides and apply state-of-the-art machine learning approaches for the 
development of a model for prognosis of BC relapse.
Results
Cohort characterization. Peptidomics profiles based on the urinary CE-MS analysis of 98 BC patients were 
evaluated according to the endpoints of BC relapse and relapse-free disease, as described in the Methods section. 
Out of the 98 BC patients, 45 developed a relapse during the follow-up period and 53 were relapse-free during the 
follow-up (Supplementary Table S1). The median follow-up time was estimated at 15.7 months (±14.6). Among 
the included BC patients, 78 (79%) were male and 20 (21%) were female. The detailed clinical characteristics of 
the study population are presented in Table 1.
Association of the previously established Ce-Ms-based urinary diagnostic panel with BC relapse. 
As a follow-up to the previously published study on CE-MS based biomarkers for the detection and monitor-
ing of BC20, assessment of the prognostic potential of the above diagnostic biomarker panel was performed. 
Association of the BC-106 score20 with BC relapse was assessed by univariate Cox regression analysis. The results 
indicated a predictive value of the BC-106 diagnostic panel for disease relapse [HR = 2.24 (95% CI, 1.22–4.11), 
p-value = 0.009, c-index = 0.60] (Fig. 1). The CE-MS BC-106 score, measured at the baseline, was able to cor-
rectly classify 60% of the patients (n = 27), who subsequently relapsed while the cystoscopy results (at the time of 
Age Mean 64.4 (±11.9)
Gender
Male 78 (79%)
Female 20 (21%)
Event
Relapse 45 (46%)
Non-relapse 53 (54%)
Follow-up [months] Mean 15.7 (±14.6)
Stage [previously resected tumor]
Papilloma 4
Tis 2
Ta 74
T1 10
T2 2
T3 1
Tx 5
Grade [previously resected tumor]
G1 22
G2 48
G3 17
Gx 2
Unknown 9
Multiplicity [previously resected tumor]
Solitary 51
Multiple 37
Unknown 10
Table 1. Patient characteristics of the study cohort (n = 98). No significant differences were detected with 
regards to age, gender, and number of events between the training and the test set.
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sampling/ baseline) were negative (Supplementary Table S2). Moreover, the diagnostic score was significantly and 
inversely correlated with the time to develop the relapse (rho = −0.28, p-value = 0.005), indicating that the higher 
the score, the shorter the time to develop a recurrence event. These results suggested a prognostic potential of the 
CE-MS peptidomics profiles in prognosis of BC relapse - a hypothesis which we further explored in this study.
Identification of BC-specific markers with prognostic potential. To fully explore the prognos-
tic potential of the CE-MS derived profiling data, statistical analysis at the single peptide level was performed. 
The study workflow is presented in Fig. 2. Peptidomics profiling datasets of 98 BC patients were randomly split 
into a training (n = 48) and an independent test set (n = 50) assuring equal distribution of cases (relapse event) 
and controls (relapse-free). Median age, gender, and event distribution were not significantly different between 
the training and test set (Supplementary Table S1). Detailed pertinent clinico-pathological information for the 
training and test sets are also listed in Supplementary Table S2. To assess the association of each peptide’s abun-
dance with disease outcome and select the set of peptides (features) for machine learning model development, 
Cox regression analysis was performed in ten re-sampling analyses, each time by randomly discarding thirty 
percent of the patients. The peptide sets that were established based on the p-value threshold (p-value < 0.1) are 
reported in Supplementary Table S3.
Development of machine learning model for relapse prediction. Based on the hypothesis that com-
bination of prognostic markers into a multi-marker classifier may increase the accuracy of prediction, we tested 
the significant peptides, which were commonly identified as significant in six (nsig.peptides = 36), seven (nsig.pep-
tides = 25), eight (nsig.peptides = 16), nine (nsig.peptides = 12) and ten (nsig.peptides = 4) Cox regression repeated analyses as 
features for the development of a machine learning model (Supplementary Table S3). A random forest algorithm 
was fed with the peptidomics profiles of the BC-specific features (as identified in the training set), while the out-
put of the modeling was evaluated on the test set. Optimization was performed via hyperparameter tuning, acting 
on the following parameters: number of trees, tree depth and number of features evaluated at each split (ranges 
specified in the Methods section). Highest performance in discriminating relapse from non-relapse patients was 
achieved using a set of 36 peptides (significant association at the significance level of 0.1, measured in at least six 
out of ten repeated analyses) (Supplementary Table S4). A detailed description of the 36 peptides is presented in 
Table 2. Following optimization, the prognostic 36-peptide model reached an accuracy of 100% (p-value < 0.001) 
in the training set. The optimal cut-off level of 0.47 for classification of relapse cases was determined in the train-
ing set based on Youden Index calculation.
Ce-Ms based validation scores indicate an increased risk for relapse. The prognostic value of the 
36-peptide model was assessed in the independent test set. A significant prognostic potential was suggested based 
on Cox regression analysis (Table 3, Fig. 3; hazard ratio (HR) of 5.76 (CI 95%, 2.35–14.12), p-value = 0.0001). 
The developed model demonstrated high positive and negative predictive values, PPV = 66% and NPV = 100%. 
Calculated Harrell c-statistic indicated a fair predictive model capacity with a concordance of 0.64, while no addi-
tional variables have been found as confounding factors (Table 3).
Among the 36 peptides that were included in the machine learning algorithm, three peptides could not be 
sequenced by using tandem mass spectrometry analysis (Table 2, Supplementary Table S4). This is most likely 
attributed to the rather large size and low abundance. The remaining 33 sequenced peptides included 23 various 
collagen alpha-1 fragments and single peptides from collagen alpha-2 (IV), collagen alpha-3 (IV) chain and col-
lagen alpha-4 (IV). Additional sequenced peptides originated from fibrinogen (FGA), polymeric immunoglob-
ulin receptor (PIGR), nebulin (NEB), peptidoglycan recognition protein 1 (PGLYRP1), forkhead box protein D2 
(FOXD2), CD99 antigen (CD99) and ankyrin repeat domain-containing protein 36 C (ANKRD36C). Peptide 
Figure 1. Kaplan-Mayer curve for the BC-106 score and disease-specific outcomes in the study cohorts (cut-
off = −0.63 was used as reported in Frantzi et al.20) Strata: red line – negative for recurrence, blue line – positive 
for recurrence. Abbreviations: HR = hazard ratio; CI = confidence interval.
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characteristics along with the hazard ratios measured for each of the model building peptides based on all pepti-
domics datasets (n = 98) are reported in Table 2.
Integration of the reported biomarkers in the context of BC pathology. To ascertain the validity of 
the reported urinary peptide biomarkers, a comparative analysis was performed considering available tissue pro-
teomics datasets from previous studies of Latosinska et al.21 and Chen et al.22 involving tissue proteomics analysis in 
specimens derived from BC patients. In the study of Latosinska et al.21 tissue proteomics datasets from BC patients 
(n = 5 NMBC of Stage Ta and n = 6 MIBC of Stages T2+) were assessed, while in the study of Chen et al.22, tissue 
proteomics datasets from paired analysis of 4 BC patients (normal epithelium and cancerous lesions; Stages T1-T4) 
were evaluated. As described above, out of the 36 significant peptide biomarkers, sequences were annotated for 33 
peptides, which corresponded to 19 distinct proteins. Among the 19 differentially excreted proteins, tissue expres-
sion was validated for 9 proteins via mass spectrometry proteomics. Those included collagen alpha-1 chains I, II, III, 
V, VI, XIV, XV, collagen alpha-2 chain IV and FGA (Supplementary Tables S5 and S6). In particular, decreased abun-
dance of urinary collagen alpha-chain II (HR = 0.36) in BC relapse cases was in line with decreased tissue abundance 
as cancer stage progressed (Fold T2+/Ta = 0.25). Additionally, an increased abundance of urinary collagen alpha-1 
chains V (HR = 2.33), VI (HR = 2.65) and FGA (HR = 2.22) was consistent with increase tissue abundance, along 
with cancer progression (Fold T2+/Ta of 1.47, 1.78 and 1.87 respectively).
In addition, BC gene expression data from the TCGA studies in tissue specimens from BC was assessed23, 
encompassing transcriptomics profiles from 406 patients (107 females and 299 males). Out of the 19 reported pro-
teins (corresponding to 33 peptide sequence biomarkers, as reported in this study), gene expression was validated 
at the tissue level for all 19 proteins apart from FGA, where gene expression data was not available. According 
to this, unfavorable prognosis for BC relapse (i.e. higher relative expression levels correlating with increased risk 
for relapse) of Ankyrin repeat domain-containing protein 36 C (ANKRD36C; HR = 2.12), Forkhead box protein 
D2 (FOXD2; HR = 3.11) collagen alpha-1 chains I (HR = 1.94), III (HR = 1.77), IV (HR = 2.33), VI (HR = 2.65), 
Figure 2. Project development workflow. The full dataset of peptidomics profiles of BC patients (n = 98) was 
split into training (n = 48) used for model development and test set (n = 50) retained for validation. Feature 
selection was performed through Cox regression analysis (10 resampling permutations) with 36 peptides found 
significantly predictive of the relapse (p-value < 0.1). Those were further used in the development of Random 
Forest-based predictive model of BC relapse. Performance of the model was evaluated on the test set and further 
optimized.
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XIV (HR = 3.15), collagen alpha-3 chain IV (HR = 8.75) and collagen alpha-4 chain IV (HR = 3.53) is in line with 
lower 5-year overall survival based on the TCGA gene expression data. In addition, biomarker nebulin (decreased 
in urine, correlating with increased risk for relapse; HR = 0.84) was also identified as a promising marker for BC 
based on the tissue gene expression data correlating with decreased overall survival (p = 0.041).
Discussion
In this study, following-up on the previously published diagnostic markers based on CE-MS proteomics analysis20 
and by enriching the analysis with longitudinal data, the prognostic performance of the CE-MS diagnostic panel 
was assessed for the risk of BC relapse. Notably, the previously published diagnostic panel for BC recurrence 
in a form of an SVM classifier (BC-106) was developed for the detecion of BC, not for prognosis of recurrence. 
However, it exhibited a significant, yet moderate prognostic value for BC relapse prediction. These initial results 
indicated a considerable prognostic value contained in at least some urinary peptides. When investigating the 
CE-MS derived profiling data at the single peptide level, several peptides were found significantly associated with 
a risk of BC relapse. Repeated statistical analysis using Cox regression was followed to shortlist the most valid 
features and integrate them into a machine learning model.
Mass spectrometry has been already applied for acquiring BC specific proteomics and metabolomics pro-
filing data and several prognostic markers based on proteomics and metabolomics studies have been reported 
in the literature, highlighting the value of -omics features in improving BC management. Urine and serum 
proteomic-based biomarkers, like SPARC24, SH3 domain binding glutamic acid-rich protein like 3 (SH3BGRL3)25 
have been recently reported as prognostic markers for BC. Moreover, according to recent metabolomics 
Protein Name Protein Symbol Mass [Da] CE time [min] Hazard ratio
Collagen alpha-3(IV) chain COL4A3 3349.54 30.97 HR: 8.75 (95% CI, 1.3–59.04), p = 0.026
— — 4846.20 26.65 HR: 6.69 (95% CI, 1.95–22.99), p = 0.003
Peptidoglycan recognition protein 1 PGLYRP1 2187.99 27.08 HR: 4.86 (95% CI, 1.47–16.02), p = 0.009
Collagen alpha-1(I) chain COL1A1 2488.11 27.95 HR: 4.26 (95% CI, 1.23–14.72), p = 0.022
Collagen alpha-1(I) chain COL1A1 1522.68 22.23 HR: 3.84 (95% CI, 0.76–19.45), p = 0.104
Collagen alpha-1(I) chain COL1A1 2103.96 33.08 HR: 3.74 (95% CI, 0.59–23.87), p = 0.163
Polymeric immunoglobulin receptor PIGR 3556.62 23.96 HR: 3.64 (95% CI, 1.29–10.23), p = 0.014
Collagen alpha-4(IV) chain COL4A4 2093.93 33.71 HR: 3.53 (95% CI, 1.3–9.56), p = 0.013
Collagen alpha-1(III) chain COL3A1 2898.31 29.25 HR: 3.15 (95% CI, 0.6–16.58), p = 0.175
Collagen alpha-1(XIV) chain COL14A1 3546.67 26.15 HR: 3.15 (95% CI, 0.99–10.02), p = 0.051
Forkhead box protein D2 FOXD2 3057.39 29.96 HR: 3.11 (95% CI, 1.18–8.16), p = 0.021
Collagen alpha-1(VI) chain COL6A1 3136.39 24.55 HR: 2.65 (95% CI, 0.82–8.6), p = 0.105
Collagen alpha-1(III) chain COL3A1 2564.15 23.00 HR: 2.4 (95% CI, 0.99–5.84), p = 0.054
Collagen alpha-1(V) chain COL5A1 3385.59 25.54 HR: 2.37 (95% CI, 0.79–7.08), p = 0.123
Collagen alpha-1(III) chain COL3A1 2323.05 22.39 HR: 2.34 (95% CI, 0.8–6.81), p = 0.12
Collagen alpha-1(V) chain COL5A1 3722.78 21.94 HR: 2.32 (95% CI, 0.84–6.44), p = 0.106
Fibrinogen alpha chain FGA 3314.48 20.21 HR: 2.22 (95% CI, 1.09–4.51), p = 0.028
— — 9866.38 20.83 HR: 2.21 (95% CI, 1.04–4.68), p = 0.039
Collagen alpha-1(III) chain COL3A1 2007.94 22.12 HR: 2.15 (95% CI, 0.84–5.48), p = 0.11
Ankyrin repeat domain-containing protein 36C ANKRD36C 5574.25 23.16 HR: 2.12 (95% CI, 0.85–5.27), p = 0.105
— — 8175.89 19.47 HR: 1.88 (95% CI, 0.75–4.71), p = 0.176
Collagen alpha-1(I) chain COL1A1 2030.92 32.65 HR: 1.79 (95% CI, 0.44–7.2), p = 0.413
Collagen alpha-1(I) chain COL1A1 2236.98 27.14 HR: 1.6 (95% CI, 0.66–3.91), p = 0.298
Collagen alpha-1(VIII) chain COL8A1 3292.54 39.27 HR: 0.89 (95% CI, 0.37–2.16), p = 0.8
Nebulin NEB 1135.49 27.79 HR: 0.84 (95% CI, 0.34–2.08), p = 0.714
Collagen alpha-1(I) chain COL1A1 2170.97 27.53 HR: 0.76 (95% CI, 0.32–1.8), p = 0.533
Collagen alpha-1(I) chain COL1A1 2319.04 33.85 HR: 0.64 (95% CI, 0.27–1.52), p = 0.31
Collagen alpha-2(IV) chain COL4A2 2264.94 43.13 HR: 0.62 (95% CI, 0.37–1.03), p = 0.063
Collagen alpha-1(XI) chain COL11A1 4169.93 33.60 HR: 0.56 (95% CI, 0.28–1.11), p = 0.096
Collagen alpha-1(I) chain COL1A1 3432.59 31.95 HR: 0.53 (95% CI, 0.21–1.33), p = 0.179
Collagen alpha-1(XV) chain COL15A1 1942.83 31.05 HR: 0.42 (95% CI, 0.11–1.55), p = 0.193
Collagen alpha-1(III) chain COL3A1 1834.84 24.21 HR: 0.37 (95% CI, 0.15–0.91), p = 0.03
Collagen alpha-1(II) chain COL2A1 1179.51 27.78 HR: 0.36 (95% CI, 0.12–1.09), p = 0.07
CD99 antigen CD99 1954.97 25.45 HR: 0.27 (95% CI, 0.1–0.71), p = 0.008
Collagen alpha-1(I) chain COL1A1 1795.79 24.93 HR: 0.26 (95% CI, 0.08–0.88), p = 0.03
Collagen alpha-1(III) chain COL3A1 1396.62 26.63 HR: 0.19 (95% CI, 0.03–1.27), p = 0.088
Table 2. Characteristics of the 36 peptides selected for the prognostic model and hazard ratios measured in the 
entire cohort (n = 98).
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studies, i.e. in a first study investigating metabolic profiles of smokers and non-smokers with BC outcome26, 
catechol-O-methyltransferase (COMT), iodotyrosine deiodinase (IYD), tubulin tyrosine ligase (TTL) were cor-
related with BC survival, while in a study investigating population-based metabolic differences associated with 
BC27, high expression of lysine demethylase 2A (KDM2A) and prolyl 3‐hydroxylase 2 (P3H2) and low expression 
of mitochondrial malic enzyme 3 (ME3) was correlated with poor survival of African American BC patients.
In the present study, increase in the number of markers (peptides) in high-dimensional classifier resulted in 
improved performance, which is in good agreement with previous studies showing a clear advantage of using 
multiple features as compared to single markers for predictive disease modeling28–30. This observation seems 
consistent, provided that the variables are truly associated with the investigated outcome to positively influence 
the model training phase. High performance of the established model indicated that the 36-peptide model is 
sufficient to embrace the heterogeneity of BC patients and forecast an accurate prognosis.
From the 36 peptides, corresponding to 19 distinct proteins, we were able to obtain sequence information for 
33 of them. The majority of sequenced peptides originated from multiple collagen fragments (mainly collagen 
alpha-1) and were found associated with both, good and poor prognosis depending on a specific sequence. Based 
on the literature and our previous CE-MS studies, collagen increase and decrease are both involved in tumor 
progression20,31, as collagen initially acts as a barrier and collagenases, such as metalloproteinases (MMPs), which 
degrade it to expose active sites and promote a pro-tumorigenic microenvironment to facilitate tumor progres-
sion. Collagen cross-linking and thickening is then necessary during extracellular matrix (ECM) remodeling and 
invasion. Elevated levels of urinary fibrinogen have already been reported in BC patients and associated with 
tumor invasiveness32,33. As such, presence of the FGA among the peptides with high prognostic value is further 
confirming its association with the disease. Increased levels of PIGR were also found associated with a higher risk 
Variable Coefficient CI l.95 CI u.95 p-value Harrell c-statistic
Age 1.75 0.74 4.15 0.20 0.54
Gender (male) 1.02 0.99 1.04 0.22 0.57
Multiplicity (solitary) 0.87 0.47 1.62 0.66 0.54
Stage
Tis 0.33 0.03 3.25 0.34
0.56
Ta 0.52 0.16 1.71 0.28
T1 0.53 0.12 2.22 0.38
T2 1.98 0.19 19.99 0.56
T3 5.11e-8 0.00 Inf 0.99
Tx 1.41 0.12 1.38 0.09
Grade
G2 1.38 0.66 2.89 0.39
0.56G3 0.96 0.36 2.52 0.93
Gx 4.53e-8 0.00 Inf 0.99
36-peptide Model 5.76 2.35 14.12 0.0001 0.64
Table 3. Univariate Cox regression analysis of potential predictor variables measured in the entire patient 
cohort and the developed machine learning model based on the test set. Abbreviations: CI = confidence 
interval.
Figure 3. Performance of the Random Forest model predicting bladder cancer relapse (measured in the test 
set). Strata: red line – negative for relapse, blue line – positive for relapse, based on established cut-off value 
(0.47). Abbreviations: HR = hazard ratio; CI = confidence interval.
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of relapse (Table 2). PIGR is a member of the immunoglobulin superfamily, involved in transcytosis of IgA and 
other immune complexes. Although it was found in the tumor tissues of BC patients, no correlation with tumor 
stage or grade could be established34. Nevertheless, association with disease relapse was, to our knowledge, not 
studied. Another immune-related protein associated with higher chance of BC relapse was peptidoglycan recog-
nition protein 1 (PGLYRP1). Interestingly, its role in anti-cancer defense was recently suggested via formation of 
cytotoxic complexes with heat shock protein 7035. Transcription factor forkhead box protein D2 (FOXD2) was 
found to be related with poor prognosis. Additionally, nuclear FOXOs are known to mediate cell cycle arrest and 
promote apoptosis36. With regards to BC, a recent analysis of long non-coding RNAs linked high FOXD2-AS1 
expression to BC progression and recurrence by acting on Act/E2F1 axis37. Among the peptides indicative of 
good prognosis and lower risk of BC relapse was CD99 antigen (CD99), which in line with the reports suggesting 
it’s oncosuppressive role in BC38,39.
Validation of the reported peptide biomarkers at the tissue level was possible through a comparative analysis 
with available mass spectrometry acquired tissue proteomics datasets21,22. The comparative analysis confirmed 
the decrease in protein abundance of collagen alpha-chain II in BC relapse cases and increased urinary abun-
dance of collagen alpha-1 chains V, VI and FGA. Importantly, for collagen alpha-1 chain V, additional reports on 
immunohistochemical staining (i.e increased staining in MIBC) support the validity for increased tissue/urine 
abundance in advanced BC40. Yet, the consistency between the tissue protein abundance and urine excretion has 
to be considered with caution, as in several observations, the differential abundance at the tissue level was not 
significant (at the level of comparison between 5 NMIBC and 6 MIBC BC proteomics datasets, considering 60% 
frequency threshold). In parallel, tissue data from gene expression analysis in BC tissue specimens (TCGA)23 
confirms ANKRD36C, FOXD2, collagen alpha-1 chains I, III, IV, VI, XIV, collagen alpha-3 chain IV and collagen 
alpha-4 chain IV as unfavorable and nebulin as favorable prognostic markers for BC outcome.
Given the high heterogeneity of BC, the results of the study are promising. Among the possible applications, 
use of the model as a tool for patient stratification e.g. for clinical trials is anticipated, as it would enable enriching 
for patients that are highly possible to develop a relapse. These patients may consequently possibly benefit from 
appropriate preventive therapeutic intervention.
Due to missing clinical parameters, a direct comparison of the performance of the prognostic model that was 
developed in this study with other methods to predict relapse was not possible. However, we were able to compare 
the predictive value with published reports on the most prominent risk calculators. In the report by Xylinas et 
al., the authors evaluated the performance of both, EORTC risk tables and the CUETO scoring model using the 
retrospective cohort consisting of 4689 patients with NMIBC16. Calculated concordance indexes of the models 
for recurrence and progression prognosis were 0.597 and 0.662 for EORTC, and 0.523 and 0.616 for CUETO 
model, respectively. Comparison with the original estimates published by EORTC and CUETO indicated reduced 
discriminative ability of the model in the reported validation study. As such, the authors pointed out the poor 
discrimination ability of the scoring models for both disease recurrence and progression in NMIBC patients, 
stressing the need for improvement of tools for risk prognosis16. Given that the model developed in our study 
reached the concordance of 0.639, it represents a good alternative to currently used prognosticators, introducing 
a truly personalized approach to relapse prognosis, based solely on urinary peptide profiles of BC patients.
Several limitations are present in this study. The low number of samples has an obvious influence on the signif-
icance of model-building features and the model itself. Moreover, the performance of the final model was assessed 
on the test set originating from the same cohort, which might introduce a bias in the evaluation. An independent 
validation cohort would be of added value in confirming the predictive capabilities of the developed approach. 
Expansion of the dataset to include more BC patients may improve the performance, providing the learning 
algorithm with more examples of the molecularly variable cases. Moreover, lack of certain parameters in the clin-
ical data made it impossible to compare the developed model to standard-of-care risk calculators. Overall, these 
promising preliminary results on the development of machine learning model based on peptidomics signatures 
for the prediction of BC relapse highlight the potential of proteomics technology in clinical applications. Efforts 
to enrich the patient database and further improve the model are foreseen in the future.
To sum up, risk stratification strategies are essential for more personalized management of BC. Prediction 
of BC relapse can assist in guiding intervention and build the foreground for prediction of treatment response. 
Incorporation of the presented model in clinical trials to further establish its clinical use and potential impact on 
decision-making will be pursued.
Methods
patient population. For this study, previously acquired and published CE-MS profiling data20 were selected 
to be further analyzed prospectively. Peptidomics profiling datasets from patients initially recruited at Erasmus 
MC, Rotterdam, with available follow-up information were included in this study. This resulted in the inclusion 
of 98 BC patients. Sample and data collection was performed in accordance with local ethics requirements and 
the Declaration of Helsinki. Written informed consent was obtained from all participants prior to study enroll-
ment and approved by Ethics Committee. For this meta-analysis (follow-up investigation), ethics approval was 
obtained by the Ethics Committee of Hannover Medical School (MHH), under the identifier Nr. 3274–2016. As 
previously described20, all urine samples were collected prior to cystoscopy and the patients were followed-up 
for a period of up to 5 years. The presence of BC was considered based on the cystoscopy results, while tumor 
stage was defined according to the TNM (tumor nodes metastases) classification41, following histological exam-
ination of tissue specimens during the biopsy. Event endpoints (relapse/non-relapse) were assigned according to 
the following criteria: (a) the timepoint when the urine measurement was acquired was considered as baseline, 
(b) the timepoint of the first relapse event was considered to define the survival time for bladder cancer patients 
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(Event = 1) and (c) relapse-free patients were considered as non-event for controls (Event = 0). The cohort char-
acteristics are summarized in Table 1 and the full list of patient clinical data is given in Supplementary Table S1.
processing of urine for peptidomics analysis and data analysis. The peptidomics datasets that were 
analyzed in this study, were originally acquired in the context of the study by Frantzi et al.20. The methodologies 
for urine sample processing and collection of peptidomics data were described in detail in the respective pub-
lications42,43. CE-MS analysis was performed using a P/ACE MDQ capillary electrophoresis system (Beckman 
Coulter, Fullerton, USA) on-line coupled to a MicroTOF MS (BrukerDaltonic, Bremen, Germany), as described 
previously20. CE-MS data was analyzed with MosaiquesVisu internal software43,44. Normalization of the CE-MS 
data was performed based on 29 collagen fragments that serve as internal standards, as previously described45. 
The obtained spectra were analyzed with Proteome Discoverer 1.2 (Thermo Scientific) (precursor mass tolerance 
of 5 ppm and fragment mass tolerance of 0.05 Da) and searched against UniProt human non-redundant database. 
Oxidation of methionine and proline were considered as variable modifications46. Detected peptides were anno-
tated, matched and deposited in a Microsoft SQL database (Human Urinary Proteome Database47,48) and used as 
an input in the present study.
statistical analysis. Based on the available follow-up information, patients experiencing recurrence 
or progression were considered as relapse cases (Event = 1), while patients without relapse were classified as 
controls (Event = 0). Only peptides detected in at least 30% of all samples were considered for the analysis 
(k = 1046). Scaling of peptide abundance values (log10 transformation) was performed in the pre-processing 
step. Additionally, missing values, often present in the peptidomics datasets due to biological (selective expression 
in pathological or physiological process) and/or technical factors (abundance below the limit of detection), were 
replaced by zeros. The prognostic performance of the previously published peptide panel for diagnosis of BC 
recurrence (BC-106) was assessed through Cox regression. Association of peptide abundance with relapse event 
was assessed in the training set (n = 48) using Cox regression analysis. The analysis was repeated ten times on 70% 
of randomly selected samples. For each peptide, a number of permutations in which it was found significant were 
calculated (significance level of 0.1) and feature sets consisting of peptides appearing significant in all ten (10/10), 
nine (9/10), eight (8/10), seven (7/10) and six (6/10) repeated analysis were created. Subsequently, machine learn-
ing prognostic models were developed based on these significant peptide sets. Statistical analysis was performed 
using R statistical software version 3.3.3.
Machine learning model development. A machine learning algorithm was implemented using package 
“H2O” in R statistical software. H2O (www.h2o.ai) is an open-source machine learning platform allowing implemen-
tation of many supervised and unsupervised machine learning algorithms49. The machine learning algorithm (script) 
is described in the Supplementary Script. Three-fold cross-validation was applied in the model building step. Models 
based on the Random Forest algorithm including different sets of biomarkers (from Cox regression analysis, as 
described above) were trained separately and optimized to identify the best performing set of biomarkers. The param-
eters selected for the optimization (ranges specified in brackets) included: a) number of trees (ntrees) [5,50], b) maxi-
mum tree depth (max_depth) [2,10], and c) number of active, randomly picked predictor columns for the dataset 
(mtries) [−1,20]. The optimization process involved acting on these parameters by testing how different values contrib-
ute to overall model performance in the independent validation set. The optimal parameters selected for the final model 
were as follows: ntrees = 11, max_depth = 3, mtries = default (−1).The optimal cut-off value was estimated in the train-
ing set, based on the the Youden index. The accuracy was further calculated by comparison of predicted classes to 
training set labels (Confusion Matrix), as Accuracy = +Sensitivity Specificity( )
2
. The prognostic performance of the model 
was assessed based on the Cox regression analysis. Positive predictive value (PPV), negative predictive value (NPV) and 
concordance (Harrell C-statistic) were calculated to assess the goodness of fit of the model.
Data Availability
The analyzed datasets generated during the current study can be available from the corresponding author on 
reasonable request.
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